Clinical trials on acute liver failure

Understanding Acute Liver Failure

Acute liver failure is a rapid decline in liver function, typically occurring in an individual without pre-existing liver disease. This condition is marked by the sudden onset of liver dysfunction, leading to coagulopathy (a condition affecting the blood’s ability to clot) and alterations in mental status, including encephalopathy. Acute liver failure can result from a variety of causes, including viral hepatitis, drug-induced liver injury, and ingestion of toxic substances such as acetaminophen overdose.

Signs, Symptoms, and Diagnosis

The clinical presentation of acute liver failure can vary, but it often includes jaundice (yellowing of the skin and eyes), abdominal pain, and mental status changes ranging from confusion to coma. Diagnosis is typically based on clinical findings, laboratory tests showing elevated liver enzymes, and impaired synthetic function of the liver, evidenced by prolonged prothrombin time. Imaging studies and sometimes liver biopsy are used to help determine the underlying cause.

Treatment and Prognosis

Treatment of acute liver failure focuses on supportive care to manage symptoms and complications, with specific therapies directed at the underlying cause if identified. In severe cases, when the liver fails to recover, liver transplantation may be the only option to save the patient’s life. The prognosis of acute liver failure varies widely depending on its cause and the rapidity of intervention. Early recognition and treatment are crucial for improving outcomes.

  • CT-EU-00042123

    Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • A study on a new treatment for acute and chronic liver failure

    The objective of this study is helping people who have a serious liver condition called acute-on-chronic liver failure (ACLF) and to investigate the efficacy of a new procedure involving plasma exchange, coupled with a special solution containing human serum albumin 5% (PE-A 5%). Patients in the experiment will be divided into two sets. Some will get the standard treatment along with plasma exchange treatment (PE-A 5%), while the others will only get the standard treatment. Everyone’s progress will be tracked for about 3 months.

    • Albutein 5%